Intended for healthcare professionals

  1. News & Views
  2. Incretins and cancer...
  3. Incretins and cancer of the bile duct in type 2 diabetes
Editorials

Incretins and cancer of the bile duct in type 2 diabetes

BMJ 2018; 363 doi: https://doi.org/10.1136/bmj.k5155 (Published 06 December 2018) Cite this as: BMJ 2018;363:k5155

Linked research

Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes
Author Information

Please note:
  • Your name will be published with your response. Include your email address in the text of your response if you want others to see it.
  • Once published, you will not have the right to remove or edit your response. The BMJ may remove or edit responses at its absolute discretion.
  • A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed
  • Rapid responses have their own URL and are retrievable in an advanced search of thebmj.com in perpetuity.
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication before sending your response. See our patient consent form.
  • By submitting this rapid response your are agreeing to our full rapid response requirements.

Note: this will be visible to readers on the site. Please only include information you are comfortable with being published.

Statement of Competing Interests

A competing interest exists when professional judgment concerning a primary interest (such as patients' welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). Find out more.

Compose eLetter

More information about text formats

Plain text

  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Terms and Conditions

Read terms and conditions

Vertical Tabs

Back to top